-21.6%
VST vs MRNA
+444.4%
-466.0%
-38.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.4% | -3.4% | +3.0% | -0.4% |
| 7D | +5.3% | -10.1% | +15.4% | +5.5% |
| 30D | +5.8% | +126.7% | -121.0% | +3.5% |
| 3M | +3.5% | +184.1% | -180.6% | +0.1% |
| 6M | -7.4% | +143.3% | -150.7% | -10.4% |
| YTD | -6.1% | +359.9% | -365.9% | -7.9% |
| 1Y | -21.6% | +454.2% | -475.8% | -20.8% |
| All | -21.6% | +444.4% | -466.0% | -20.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling